Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Griffith

Showing results (91-100 of 115) with videos related to

Pageof 12
Sort By:
Oncotarget|February 5, 2017
Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial diseaseJulie V Philley, Anbarasu Kannan, David E Griffith, et al.
Frontiers in Cellular and Infection Microbiology|November 15, 2023
<i>Ex vivo</i> and <i>in vivo</i> evidence that cigarette smoke-exposed T regulatory cells impair host immunity against <i>Mycobacterium tuberculosis</i>Xiyuan Bai, Deepshikha Verma, Cindy Garcia, et al.
International Journal of Systematic and Evolutionary Microbiology|November 16, 2017
Mycobacterium abscessus, a taxonomic puzzleEnrico Tortoli, Tomas A Kohl, Barbara A Brown-Elliott, et al.
Antimicrobial Agents and Chemotherapy|July 8, 2020
Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant TuberculosisMohammad H Al-Shaer, Anne-Grete Märtson, Wael A Alghamdi, et al.
The Lancet. Infectious Diseases|January 29, 2022
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseasesChristoph Lange, Erik C Böttger, Emmanuelle Cambau, et al.
Pulmonary Therapy|April 8, 2025
Trial Conduct, Baseline Characteristics, and Symptom Burden of Patients in the ARISE StudyCharles L Daley, James D Chalmers, Patrick A Flume, et al.
American Journal of Respiratory and Critical Care Medicine|February 6, 2007
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseasesDavid E Griffith, Timothy Aksamit, Barbara A Brown-Elliott, et al.
American Journal of Respiratory and Critical Care Medicine|October 18, 2016
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung DiseaseKenneth N Olivier, David E Griffith, Gina Eagle, et al.
Annals of the American Thoracic Society|December 16, 2020
Amikacin Liposome Inhalation Suspension for <i>Mycobacterium avium</i> Complex Lung Disease: A 12-Month Open-Label Extension Clinical TrialKevin L Winthrop, Patrick A Flume, Rachel Thomson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 26, 2022
α1-Antitrypsin Binds to the Glucocorticoid Receptor with Anti-Inflammatory and Antimycobacterial Significance in MacrophagesXiyuan Bai, An Bai, Michele Tomasicchio, et al.
Pageof 12

Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Oncotarget|February 5, 2017
Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial diseaseJulie V Philley, Anbarasu Kannan, David E Griffith, et al.
Frontiers in Cellular and Infection Microbiology|November 15, 2023
<i>Ex vivo</i> and <i>in vivo</i> evidence that cigarette smoke-exposed T regulatory cells impair host immunity against <i>Mycobacterium tuberculosis</i>Xiyuan Bai, Deepshikha Verma, Cindy Garcia, et al.
International Journal of Systematic and Evolutionary Microbiology|November 16, 2017
Mycobacterium abscessus, a taxonomic puzzleEnrico Tortoli, Tomas A Kohl, Barbara A Brown-Elliott, et al.
Antimicrobial Agents and Chemotherapy|July 8, 2020
Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant TuberculosisMohammad H Al-Shaer, Anne-Grete Märtson, Wael A Alghamdi, et al.
The Lancet. Infectious Diseases|January 29, 2022
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseasesChristoph Lange, Erik C Böttger, Emmanuelle Cambau, et al.
Pulmonary Therapy|April 8, 2025
Trial Conduct, Baseline Characteristics, and Symptom Burden of Patients in the ARISE StudyCharles L Daley, James D Chalmers, Patrick A Flume, et al.
American Journal of Respiratory and Critical Care Medicine|February 6, 2007
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseasesDavid E Griffith, Timothy Aksamit, Barbara A Brown-Elliott, et al.
American Journal of Respiratory and Critical Care Medicine|October 18, 2016
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung DiseaseKenneth N Olivier, David E Griffith, Gina Eagle, et al.
Annals of the American Thoracic Society|December 16, 2020
Amikacin Liposome Inhalation Suspension for <i>Mycobacterium avium</i> Complex Lung Disease: A 12-Month Open-Label Extension Clinical TrialKevin L Winthrop, Patrick A Flume, Rachel Thomson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 26, 2022
α1-Antitrypsin Binds to the Glucocorticoid Receptor with Anti-Inflammatory and Antimycobacterial Significance in MacrophagesXiyuan Bai, An Bai, Michele Tomasicchio, et al.
Pageof 12